Enoxaparin sodium and Bone lesion - a phase IV clinical study of FDA data

Summary:

Bone lesion is reported as a side effect among people who take Enoxaparin sodium (enoxaparin sodium), especially for people who are male, 60+ old, also take Revlimid, and have Neoplasm malignant.

The phase IV clinical study analyzes which people have Bone lesion when taking Enoxaparin sodium. It is created by eHealthMe based on reports of 24,091 people who have side effects when taking Enoxaparin sodium from the FDA, and is updated regularly.

What is Enoxaparin sodium?

Enoxaparin sodium has active ingredients of enoxaparin sodium. It is often used in deep venous thrombosis. eHealthMe is studying from 24,181 Enoxaparin sodium users. Check the latest studies of Enoxaparin sodium.

What is Bone lesion?

Bone lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries) is found to be associated with 859 drugs and 500 conditions by eHealthMe. Check the latest studies of Bone lesion.

On Jul, 06, 2026

24,091 people reported to have side effects when taking Enoxaparin sodium.
Among them, 16 people (0.07%) have Bone lesion.

Could Enoxaparin sodium cause Bone lesion?

Among these 16 people:

What is the gender of people who have Bone lesion when taking Enoxaparin sodium? *

female: 37.5 %
male: 62.5 %

What is the age of people who have Bone lesion when taking Enoxaparin sodium? *

What are other drugs people take besides Enoxaparin sodium? *

What are other side effects people have besides Bone lesion? *

Osteomyelitis (infection of bone): 12 people, 75.00%
Pulmonary Embolism (blockage of the main artery of the lung): 11 people, 68.75%
Injury: 10 people, 62.50%
Pain: 10 people, 62.50%
Stress And Anxiety: 10 people, 62.50%
Diarrhea: 8 people, 50.00%
Osteonecrosis Of Jaw (death of bone of jaw): 8 people, 50.00%
Metastases To Bone (cancer spreads to bone): 7 people, 43.75%
Haemorrhage (bleeding): 6 people, 37.50%
Swelling: 6 people, 37.50%

What are the existing conditions these people have? *

Neoplasm Malignant (cancer tumour): 6 people, 37.50%
Multiple Myeloma (cancer of the plasma cells): 3 people, 18.75%
Metastases To Bone (cancer spreads to bone): 2 people, 12.50%
Pulmonary Vein Occlusion (blockage in pulmonary vein): 1 person, 6.25%
Metastases To Spine (cancer spreads to spine): 1 person, 6.25%
High Blood Pressure: 1 person, 6.25%
Fibrous Dysplasia Of Bone (an abnormal bone growth where normal bone is replaced with fibrous bone tissue): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Enoxaparin sodium and have Bone lesion?

- Check whether Bone lesion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Enoxaparin sodium:

Enoxaparin sodium (24,181 reports)

Bone lesion treatments and more:

Bone lesion (6,686 reports)

Browse all side effects of Enoxaparin sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bone lesion:

Bone lesion (859 drugs)

Browse all the conditions that are associated with Bone lesion:

Bone lesion (500 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on enoxaparin sodium (the active ingredients of Enoxaparin sodium) and Enoxaparin sodium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.